BioCentury
ARTICLE | Company News

OncoSec to conduct Phase II melanoma trial combining its ImmunoPulse IL-12 and Keytruda

May 12, 2017 6:48 PM UTC

OncoSec Medical Inc. (NASDAQ:ONCS) said it will sponsor and conduct the Phase II PISCES trial to evaluate its ImmunoPulse IL-12 in combination with PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK). The trial will enroll about 48 patients with metastatic melanoma that progressed on previous treatment with an anti-PD-1 therapy.

ImmunoPulse IL-12 is a DNA plasmid coding for IL-12 delivered via electroporation. It is in Phase II testing for various cancers and has Fast Track designation to treat metastatic melanoma. ...